LyrArc Article Gist
In a new twist drugmaker AbbieVie will bring out less costly versions of Humira in Europe where its patents have expired and still keep the U.S. market at higher Humira prices using a thicket of patents. Reports show pharmaceutical drug pricing as a major issue in U.S. midterm elections. Biologic drugs are costly. In this case Humira will sell at a 10-20% discount in Europe. Abbie Vie countered by getting hundreds of new patents in the U.S. to continue selling at high prices.

LyrArc Article Gist
Arthritis drug Humira from Abbvie is shown in this NYT report as having made $114 billion from Humira using the US patent system to delay the introduction of competing products that would have lowered prices for Americans suffering from arthritis. NYT says the114 billion was made just since 2016 when competing products were coming to market. In 2022 this is ending as nine competitors including Pfizer come up with their competing products. In many ways the system of market competition does not operate in the way textbooks or free market advocates say. It is considered ok to engineer advantage within what is a supposedly a market competition system and to turn a blind eye to it. Is it acceptable when it comes to health products and when prices increase from the exorbitant to the outrageous. The Inflation Reduction Act of president Biden included efforts to prevent just such abuses of a market competition system to restore fairness after years of egregious behaviours.

LyrArc Article Gist
Abbott Labs will split into two publicly traded companies, with a medical products company including products such as Similac, Ensure and stent devices, and a pharmaceutical company that would have its Humira rheumatoid arthritis therapy Humira. Humira generates about $8 billion in sales, but faces patent expiration in 2016 and competition from a new drrug expected from Pfizer, as well as generics. Abbott's CEO sees the opportunities in the two products falling in different areas. The medical products business has greater potential in emerging markets, and will require a different focus from the slower growing pharmaceutical business facing competition and payor cost pressures. The medical product company includes a drug coated stent Xience, with $1.5 billion in sales, which has improved prospects as J&J is leaving the stent business. The medical products business sales are 40% from emerging markets, and 40% of revenue comes from patients not from cost conscious governments or insurers, according to CEO White. Its the emerging markets emphasis that convinced White to go with the split. Richard Gonzalez who runs the pharmaceutical business will head the pharmaceutical company, and CEO Miles White will run the medical products company....